Microba Life Sciences Ltd
ASX:MAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Microba Life Sciences Ltd
Selling, General & Administrative
Microba Life Sciences Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Microba Life Sciences Ltd
ASX:MAP
|
Selling, General & Administrative
-AU$21.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Selling, General & Administrative
-AU$5.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Selling, General & Administrative
-AU$539.8m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Selling, General & Administrative
-AU$342.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Apiam Animal Health Ltd
ASX:AHX
|
Selling, General & Administrative
-AU$90.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Selling, General & Administrative
-AU$798.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
Microba Life Sciences Ltd
Glance View
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm specializes in the analysis of gut microbiome and promotes development in pathology services, therapeutics and diagnostics based on the microbiome. The firm's flagship product is the Microba Insight, a sampling kit that allows the public to analyze personal gut microbiome. Its discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The company also offers support solutions to researchers.
See Also
What is Microba Life Sciences Ltd's Selling, General & Administrative?
Selling, General & Administrative
-21.2m
AUD
Based on the financial report for Jun 30, 2025, Microba Life Sciences Ltd's Selling, General & Administrative amounts to -21.2m AUD.
What is Microba Life Sciences Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-25%
Over the last year, the Selling, General & Administrative growth was -33%. The average annual Selling, General & Administrative growth rates for Microba Life Sciences Ltd have been -27% over the past three years , -25% over the past five years .
